Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 July 2014Website:
http://www.sagerx.comNext earnings report:
14 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
SAGE Latest News
Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $1.53 per share versus the Zacks Consensus Estimate of a loss of $1.52. This compares to loss of $2.81 per share a year ago.
NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Therapeutics, Inc. (“Sage” or “the Company”) (NASDAQ: SAGE) and certain of its officers.
NEW YORK , Oct. 28, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE). Shareholders who purchased shares of SAGE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sage securities between April 12, 2021, and July 23, 2024, inclusive (the "Class Period").
NEW YORK , Oct. 26, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the "Class Period"), of the important October 28, 2024 lead plaintiff deadline. So what: If you purchased Sage securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming October 28, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Sage Therapeutics, Inc. (“Sage” or the “Company”) (NASDAQ: SAGE) securities between April 12, 2021 and July 23, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On August 4, 2023, Sage disclosed that the U.S. Food and Dr.
BENSALEM, Pa. , Oct. 24, 2024 /PRNewswire/ -- Law Offices of Howard G.
NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sage securities between April 12, 2021, and July 23, 2024, inclusive (the "Class Period").
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between April 12, 2021 and July 23, 2024, both dates inclusive (the “Class Period”). Sage Therapeutics is a biopharmaceutical company that develops and commercializes brain health medicines. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866.
What type of business is Sage Therapeutics?
Sage Therapeutics, Inc. is a biopharmaceutical company that specializes in the development and commercialization of drugs for the treatment of central nervous system disorders (depression, neuropsychiatric and neurological deviations). Founded in 2010, the company started its operations as Sterogen Biopharma, Inc. in 2011, changed its name to the current one. The corporate headquarters is located in Cambridge, Massachusetts. At the moment, the company has one product that was approved by the FDA in March 2019, and its commercialization began in the second half of that year. ZULRESSO is a drug whose active ingredient is identical to a natural neuroactive steroid. It is used for the treatment of postpartum depression.
What sector is Sage Therapeutics in?
Sage Therapeutics is in the Healthcare sector
What industry is Sage Therapeutics in?
Sage Therapeutics is in the Biotechnology industry
What country is Sage Therapeutics from?
Sage Therapeutics is headquartered in United States
When did Sage Therapeutics go public?
Sage Therapeutics initial public offering (IPO) was on 18 July 2014
What is Sage Therapeutics website?
https://www.sagerx.com
Is Sage Therapeutics in the S&P 500?
No, Sage Therapeutics is not included in the S&P 500 index
Is Sage Therapeutics in the NASDAQ 100?
No, Sage Therapeutics is not included in the NASDAQ 100 index
Is Sage Therapeutics in the Dow Jones?
No, Sage Therapeutics is not included in the Dow Jones index
When was Sage Therapeutics the previous earnings report?
No data
When does Sage Therapeutics earnings report?
The next expected earnings date for Sage Therapeutics is 14 February 2025